Hitachi Constructs Japan's First Platform for Integrated Management of Cell and Tracing Information throughout the Value Chain for Regenerative Medicine Products through Collaborative Creation with Alfresa and Others

Hitachi, Ltd. (TSE:6501; "Hitachi") has constructed a platform for the integrated management of cell and tracing information throughout the value chain, from cell collection, through production and transport, to the administration of regenerative medicine products(1) through collaborative creation with Alfresa Corporation ("Alfresa"), pharmaceutical companies, medical institutions, and others. Hitachi will start practical operation of the platform in 2021 following an operational test and Alfresa will be one of the first users of the platform.